Tumor autocrine motility factor is an angiogenic factor that stimulates endothelial cell motility

被引:26
作者
Funasaka, T
Haga, A
Raz, A
Nagase, H
机构
[1] Gifu Pharmaceut Univ, Dept Hyg, Gifu 502, Japan
[2] Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48210 USA
关键词
AMF; gp78; cell motility; tumor angiogenesis; metastasis;
D O I
10.1006/bbrc.2001.4912
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Autocrine motility factor (AMF) is a type of tumor-secreted cytokine that primarily stimulates tumor cell motility via receptor-mediated signaling pathways and is thought to be connected to tumor progression and metastasis. Using in vivo models, we showed that critical neovascularization responded to a biological amount of AMF. This angiogenic activity was fixed by specific inhibitors against AMF. AMF stimulated in vitro motility of human umbilical vein endothelial cells (HUVECs), inducing the expression of cell surface AMF receptor localizing a single predominant perinuclear pattern closely correlated with its motile ability. AMF also elicited the formation of tube-like structures mimicking angiogenesis when HUVECs were grown in three-dimensional type I collagen gels. We further immunohistochemically detected AMF receptors on the surrounding sites of newborn microvessels. These findings suggest that AMF is a possible tumor progressive angiogenic factor which may act in a paracrine manner for the endothelial cells in the clinical neoplasm, and it will be a new target for anti-angiogenic treatment. (C) 2001 Academic Press.
引用
收藏
页码:1116 / 1125
页数:10
相关论文
共 54 条
[1]  
ALBRECHTBUEHLER G, 1977, CELL, V11, P359
[2]   THE DIAGNOSTIC VALIDITY OF THE SERUM TUMOR-MARKER PHOSPHOHEXOSE ISOMERASE (PHI) IN PATIENTS WITH GASTROINTESTINAL, KIDNEY, AND BREAST-CANCER [J].
BAUMANN, M ;
KAPPL, A ;
LANG, T ;
BRAND, K ;
SIEGFRIED, W ;
PATEROK, E .
CANCER INVESTIGATION, 1990, 8 (3-4) :351-356
[3]   Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils [J].
Chertov, O ;
Michiel, DF ;
Xu, LL ;
Wang, JM ;
Tani, K ;
Murphy, WJ ;
Longo, DL ;
Taub, DD ;
Oppenheim, JJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :2935-2940
[4]  
Dosquet C, 1997, CLIN CANCER RES, V3, P2451
[5]   SERUM PHOSPHOHEXOSE ISOMERASE ACTIVITIES IN PATIENTS WITH COLORECTAL-CANCER [J].
FILELLA, X ;
MOLINA, R ;
JO, J ;
MAS, E ;
BALLESTA, AM .
TUMOR BIOLOGY, 1991, 12 (06) :360-367
[6]   ANGIOGENIC FACTORS [J].
FOLKMAN, J ;
KLAGSBRUN, M .
SCIENCE, 1987, 235 (4787) :442-447
[7]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[8]   WHAT IS THE EVIDENCE THAT TUMORS ARE ANGIOGENESIS DEPENDENT [J].
FOLKMAN, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (01) :4-6
[9]   TUMOR-NECROSIS-FACTOR TYPE-ALPHA, A POTENT INHIBITOR OF ENDOTHELIAL-CELL GROWTH-INVITRO, IS ANGIOGENIC INVIVO [J].
FRATERSCHRODER, M ;
RISAU, W ;
HALLMANN, R ;
GAUTSCHI, P ;
BOHLEN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (15) :5277-5281
[10]   CLINICAL IMPORTANCE OF THE DETERMINATION OF TUMOR ANGIOGENESIS IN BREAST-CARCINOMA - MUCH MORE THAN A NEW PROGNOSTIC TOOL [J].
GASPARINI, G ;
HARRIS, AL .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :765-782